190 related articles for article (PubMed ID: 31678771)
1. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
Walter T; Lepage C; Coriat R; Barbier E; Cadiot G; Caroli-Bosc FX; Aparicio T; Bouhier-Leporrier K; Hentic-Dhome O; Gay F; Dupont-Gossart AC; Duluc M; Lepere C; Lecomte T; Smith D; Petorin C; Di-Fiore F; Ghiringhelli F; Legoux JL; Guimbaud R; Baudin E; Lombard-Bohas C; de Baère T;
Eur J Cancer; 2019 Dec; 123():92-100. PubMed ID: 31678771
[TBL] [Abstract][Full Text] [Related]
2. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
Chen JX; Wileyto EP; Soulen MC
Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
[TBL] [Abstract][Full Text] [Related]
3. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Yao JC; Fazio N; Singh S; Buzzoni R; Carnaghi C; Wolin E; Tomasek J; Raderer M; Lahner H; Voi M; Pacaud LB; Rouyrre N; Sachs C; Valle JW; Fave GD; Van Cutsem E; Tesselaar M; Shimada Y; Oh DY; Strosberg J; Kulke MH; Pavel ME;
Lancet; 2016 Mar; 387(10022):968-977. PubMed ID: 26703889
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver.
Gaur SK; Friese JL; Sadow CA; Ayyagari R; Binkert CA; Schenker MP; Kulke M; Baum R
Cardiovasc Intervent Radiol; 2011 Jun; 34(3):566-72. PubMed ID: 21431978
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Pavel ME; Singh S; Strosberg JR; Bubuteishvili-Pacaud L; Degtyarev E; Neary MP; Carnaghi C; Tomasek J; Wolin E; Raderer M; Lahner H; Valle JW; Pommier R; Van Cutsem E; Tesselaar MET; Fave GD; Buzzoni R; Hunger M; Eriksson J; Cella D; Ricci JF; Fazio N; Kulke MH; Yao JC
Lancet Oncol; 2017 Oct; 18(10):1411-1422. PubMed ID: 28838862
[TBL] [Abstract][Full Text] [Related]
8. Hepatic-directed Therapies in Patients with Neuroendocrine Tumors.
Kennedy AS
Hematol Oncol Clin North Am; 2016 Feb; 30(1):193-207. PubMed ID: 26614377
[TBL] [Abstract][Full Text] [Related]
9. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
10. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study.
Maire F; Lombard-Bohas C; O'Toole D; Vullierme MP; Rebours V; Couvelard A; Pelletier AL; Zappa M; Pilleul F; Hentic O; Hammel P; Ruszniewski P
Neuroendocrinology; 2012; 96(4):294-300. PubMed ID: 22507901
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
[TBL] [Abstract][Full Text] [Related]
13. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases.
Riemsma RP; Bala MM; Wolff R; Kleijnen J
Cochrane Database Syst Rev; 2013 Apr; (4):CD009498. PubMed ID: 23633373
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
Singh S; Carnaghi C; Buzzoni R; Pommier RF; Raderer M; Tomasek J; Lahner H; Valle JW; Voi M; Bubuteishvili-Pacaud L; Lincy J; Wolin E; Okita N; Libutti SK; Oh DY; Kulke M; Strosberg J; Yao JC; Pavel ME; Fazio N;
Neuroendocrinology; 2018; 106(3):211-220. PubMed ID: 28554173
[TBL] [Abstract][Full Text] [Related]
15. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
17. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Rose DB; Nellesen D; Neary MP; Cai B
J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
[TBL] [Abstract][Full Text] [Related]
18. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
Hung JS; Chang MC; Lee PH; Tien YW
World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
[TBL] [Abstract][Full Text] [Related]
19. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
[TBL] [Abstract][Full Text] [Related]
20. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.
Dong XD; Carr BI
Med Oncol; 2011 Dec; 28 Suppl 1():S286-90. PubMed ID: 21107755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
